Abstract:AIM:To evaluate effects of UDP-glucuronosyltransferase1A1 (UGT1A1) and thymidylate synthetase (TS) gene polymorphisms on irinotecan in metastatic colorectal cancer (mCRC).METHODS:Two irinotecan- and fluorouracil-based regimens, FOLFIRI and IFL, were selected as second-line therapy for 138 Chinese mCRC patients. Genomic DNA was extracted from peripheral blood samples before treatment. UGT1A1 and TS gene polymorphisms were determined by direct sequencing and restriction fragment length polymorphism, respectively. Gene polymorphisms of UGT1A1*28, UGT1A1*6 and promoter enhancer region of TS were analyzed. The relationship between genetic polymorphisms and clinical outcome, that is, response, toxicity and survival were assessed. Pharmacokinetic analyses were performed in a subgroup patients based on different UGT1A1 genotypes. Plasma concentration of irinotecan and its active metabolite SN-38 and inactive metabolite SN-38G were determined by high performance liquid chromatography. Differences in irinotecan and its metabolites between UGT1A1 gene variants were compared.RESULTS:One hundred and eight patients received the FOLFIRI regimen, 29 the IFL regimen, and one irinotecan monotherapy. One hundred and thirty patients were eligible for toxicity and 111 for efficacy evaluation. One hundred and thirty-six patients were tested for UGT1A1*28 and *6 genotypes and 125 for promoter enhancer region of TS. Patients showed a higher frequency of wild-type UGT1A1*28 (TA6/6) compared with a Caucasian population (69.9% vs 45.2%). No significant difference was found between response rates and UGT1A1 genotype, although wild-type showed lower response rates compared with other variants (17.9% vs 24.2% for UGT1A1*28, 15.7% vs 26.8% for UGT1A1*6). When TS was considered, the subgroup with homozygous UGT1A1*28 (TA7/7) and non-3RG genotypes showed the highest response rate (33.3%), while wild-type UGT1A1*28 (TA6/6) with non-3RG only had a 13.6% response rate, but no significant difference was found. Logistic regression showed treatment duration was closely linked to clinical response. In toxicity comparison, UGT1A1*28 TA6/6 was associated with lower incidence of grade 2-4 diarrhea (27.8% vs 100%), and significantly reduced the risk of grade 4 neutropenia compared with TA7/7 (7.8% vs 37.5%). Wild-type UGT1A1*6 (G/G) tended to have a lower incidence of grade 3/4 diarrhea vs homozygous mutant (A/A) genotype (13.0% vs 40.0%). Taking UGT1A1 and TS genotypes together, lower incidence of grade 2-4 diarrhea was found in patients with non-3RG TS genotypes, when TA6/6 was compared with TA7/7 (35.3% vs 100.0%). No significant association with time to progression (TTP) and overall survival (OS) was observed with either UGT1A1 or TS gene polymorphisms, although slightly longer TTP and OS were found with UGT1A1*28 (TA6/6). Irinotecan PK was investigated in 34 patients, which showed high area under concentration curve (AUC) of irinotecan and SN-38, but low AUC ratio (SN-38G / SN-38) in those patients with UGT1A1*28 TA7/7.CONCLUSION:A distinct distribution pattern of UGT1A1 genotypes in Chinese patients might contribute to relatively low toxicity associated with irinotecan and 5-fluorouracil in mCRC patients.

Prediction of Drug–Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation

Combination of dabrafenib with irinotecan might trigger off a higher frequency of adverse events by pharmacokinetic interaction

The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk

Differential Effects of Ketoconazole, Fluconazole, and Itraconazole on the Pharmacokinetics of Pyrotinib in Vitro and in Vivo

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite

Potential Drug-drug Interaction between Dabrafenib and Insulin Secretagogue Repaglinide

Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases

Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors Via Inhibition of UDP-Glucuronosyltransferases

Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.

Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronosyltransferase (UGT) 1A1.

The UGT1A1∗28 Polymorphism Correlates with Erlotinib’s Effect on SN-38 Glucuronidation

In vitro inhibitory effects of selumetinib on activity of human UDP-glucuronosyltransferases and prediction of in vivo drug-drug interactions

Cabozantinib Carries the Risk of Drug-Drug Interactions Via Inhibition of UDPglucuronosyltransferase (UGT) 1A9

Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases

Inhibitory effect of imperatorin on dabrafenib metabolism in vitro and in vivo

Avapritinib Carries the Risk of Drug Interaction Via Inhibition of UDP-Glucuronyltransferase (UGT) 1A1.

In Vitro Inhibition of Human UDP-glucuronosyltransferase (UGT) 1A1 by Osimertinib, and Prediction of in Vivo Drug-Drug Interactions.

Telmisartan Utilization in Clinic Affects the Clinical Utilization of Gastrointestinal Cancer Drugs

UGT1A1 Predicts Outcome in Colorectal Cancer Treated with Irinotecan and Fluorouracil.

Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: Prediction of in vivo drug-drug interactions

Inhibition of human UDP-glucuronosyltransferase enzyme by ripretinib: Implications for drug-drug interactions